Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
Harvard Business School
Boehringer Ingelheim
McKinsey
Dow

Last Updated: January 26, 2022

DrugPatentWatch Database Preview

Claims for Patent: 8,512,932

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 8,512,932
Title:Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
Abstract: Methods are provided for drying a particle. Specifically, there is provided a spray-dried diketopiperazine-insulin particle formulation having improved aerodynamic performance and in which the active agent is more stabile and efficiently delivered as compared to that of the lyophilized diketopiperazine-insulin formulation. The dry powders have utility as pharmaceutical formulations for pulmonary delivery.
Inventor(s): Wilson; Bryan R. (Bedford, NY), Grant; Marshall (Newtown, CT)
Assignee: MannKind Corporation (Valencia, CA)
Application Number:13/239,696
Patent Claims:1. A method of preparing a dry powder medicament with an improved pharmaceutic property, comprising a) providing a solution of a diketopiperazine having acidic or basic side chains; b) forming particles comprising the diketopiperazine by adjusting the pH of the solution, resulting in a suspension of particles of the diketopiperazine with acidic or basic side chains in a solvent, and optionally loading said particles with an active agent, then c) removing solvent by spray drying to obtain a dry powder, wherein the dry powder has an improved pharmaceutic property as compared to a dry powder obtained by removing solvent by lyophilization, wherein the improved pharmaceutic property is selected from the group consisting of increased density of the powder, increased aerodynamic performance of the powder, and improved stability of the active agent, if present.

2. The method of claim 1, wherein said diketopiperazine is a diketopiperazine having the formula 2,5-diketo-3,6-di(4-X-aminobutyl)piperazine, wherein X is selected from the group consisting of succinyl, glutaryl, maleyl, and fumaryl.

3. The method of claim 2, wherein the diketopiperazine is fumaryl diketopiperazine.

4. The method of claim 1, comprising loading the particle with an active agent prior to the solvent removal step.

5. The method of claim 4, wherein said loading step comprises: providing a solution or a suspension of the active agent; and adding said solution or suspension of active agent to the suspension of particles of the diketopiperazine with acidic or basic side chains.

6. The method of claim 4, wherein the active agent is selected from the group consisting of insulin, calcitonin, parathyroid hormone 1-34 ((PTH(1-34)), octreotide, leuprolide, RSV peptide, felbamate, cannabinoid antagonists and/or agonists, muscarinic antagonists and/or agonists, heparin, low molecular weight heparin, cromolyn, sildenafil, vardenafil, tadalafil, growth hormone, AZT, DDI, GCSF, lamotrigine, chorionic gonadotropin releasing factor, luteinizing release hormone, .beta.-galactosidase, GLP-1, exendins 1-4 and ghrelin.

7. The method of claim 4, wherein the active agent is a peptide or protein.

8. The method of claim 6, wherein the active agent is insulin or an analogue thereof.

9. The method of claim 1, wherein said improved pharmaceutic property is improved aerodynamic performance of the particle.

10. The method of claim 1, wherein said improved pharmaceutic property is increased density of the powder.

11. The method of claim 4, wherein said improved pharmaceutic property is improved stability of the active agent of the particle.

12. The method of claim 9, wherein said aerodynamic performance is measured by the percent respirable fraction on a cartridge fill.

13. The method of claim 12, wherein the percent respirable fraction is greater than about 40%.

14. The method of claim 12, wherein the percent respirable fraction is greater than about 50%.

15. The method of claim 12, wherein the percent respirable fraction is greater than about 60%.

16. A dry powder prepared according to the method of claim 1.

17. A method of preparing a dry powder medicament with an improved pharmaceutic property, comprising the steps of: (a) providing a solution of a diketopiperazine having acidic or basic side chains; (b) providing a solution of an active agent; (c) forming particles of the diketopiperazine by adjusting the pH of the solution, resulting in a suspension of particles of the diketopiperazine with acidic or basic side chains in a solvent; (d) combining the diketopiperazine particles and the active agent solution; and (e) after steps (a)-(d), removing the solvent by spray drying to obtain a dry powder, wherein the dry powder obtained by spray drying has an improved pharmaceutic property as compared to a dry powder obtained by removing solvent by lyophilization, wherein the improved pharmaceutic property is selected from the group consisting of improved stability of the active agent, increased density of the powder, and improved aerodynamic performance of the dry powder.

18. The method of claim 17, wherein said diketopiperazine is a diketopiperazine having the formula 2,5-diketo-3,6-di(4-X-aminobutyl)piperazine, wherein X is selected from the group consisting of succinyl, glutaryl, maleyl, and fumaryl.

19. The method of claim 18, wherein the diketopiperazine is fumaryl diketopiperazine.

20. The method of claim 17, wherein said improved pharmaceutic property is improved stability of the active agent.

21. The method of claim 17, wherein said improved pharmaceutic property is improved aerodynamic performance of the particle.

22. The method of claim 17, wherein said improved pharmaceutic property is increased density of the powder.

23. The method of claim 21, wherein said aerodynamic performance is measured by the percent respirable fraction on a cartridge fill.

24. The method of claim 23, wherein the percent respirable fraction is greater than about 40%.

25. A dry powder prepared according to the method of claim 17.

26. A method for delivering an active agent to a patient in need thereof, comprising administering to the patient an effective amount of the dry powder of claim 16.

27. A method for delivering an active agent to a patient in need thereof, comprising administering to the patient an effective amount of the dry powder of claim 25.

Details for Patent 8,512,932

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 1974-01-15 ⤷  Sign up for a Free Trial 2026-02-22
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 1984-12-27 ⤷  Sign up for a Free Trial 2026-02-22
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 1985-02-15 ⤷  Sign up for a Free Trial 2026-02-22
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
Moodys
McKinsey
Dow
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.